The FDA approved cemiplimab-rwlc (Libtayo) for treatment of locally advanced, or metastatic, cutaneous squamous cell carcinoma (CSCC). This is the first drug treatment approved for advanced CSCC, the second most common cancer in the U.S. Please see the FDA website for more information.
Recent Posts
- Empowering EMS with PEPID’s EMS Suite: A Leap Towards Safer and More Efficient Patient Care
- The Doctor is In: A Guide to Clinical Decision Support Apps
- Surviving the Storm: The Role of Disaster Preparedness in Emergency Medicine
- Beyond Bedside Manner: Creative Solutions for Dealing with Unique Patient Challenges in the Emergency Department
- PEPID’s Impactful Collaboration with OKB Hope Foundation: Elevating Rural Healthcare